Similarly, several studies have evaluated the effects of different SGLT2 inhibitors including empagliflozin, dapagliflozin, luseogliflozin, and ipragliflozin EAT in patients with T2DM, both with and without obesity. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.